Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In pregnant women, severe malaria is responsible for high maternal mortality, and uncomplicated malaria results in in high morbidity. Careful documentation of treatments showed that, although not all drugs are available for pregnant women, early treatment can greatly increase the outcome of the pregnancy, and give that child a better chance at a productive life.

Q: Why is Malaria in pregnancy particularly harmful?

Rose McGready: On the Thai-Myanmar border where I work, the most obvious harm we see is when a pregnant woman dies from severe malaria. As a clinician, sending home the husband with the two children without the mother is very harrowing, and made worse because these deaths are preventable. We see tens of thousand of these deaths every year.

Uncomplicated malaria is also harmful but it is much more sinister. The mother might not have any symptoms at all of malaria, but her foetus is on a pathway to be born with a low birth weight and premature. Then it has a higher risk of mortality in the first year of life, it cannot reach its full growth potential which means it will be short in stature and not do as well at school or at job attainment. When a baby born too small reaches adulthood, they suffer diseases like diabetes and hypertension. So malaria sets up this really negative health cycle, which is not just destructive to the individual but to the countries endemic for malaria.

Q: How do you treat malaria in pregnancy?

RMG: I would really rather prevent malaria in pregnancy, failing that we treat. Treatment is fairly similar to uncomplicated malaria in non-pregnant patients, except for the first trimester, where we use quinine rather than an artemisinin derivative. Pregnancy already makes you susceptible to anaemia, so we are very vigilant at looking for and treating anaemia.

Severe malaria in pregnancy has got a very high mortality rate. We would like to take care of these women in intensive care, but in most rural and resource-poor settings, these are very hard to access. For example, if I had ten women with severe malaria in intensive care in good facilities and gave them my best drug - intravenous artesunate - still two of them will die, they won't go home. Our intention is to save the life of the mother, but a lot of those women will also lose their baby.

Q: What is your approach to malaria in pregnancy?

RMG: Where we are on the Thai-Myanmar border, the drugs that we would normally give a woman to prevent malaria have all been lost to resistance, so we cannot prevent with drugs. We also know that two thirds of our deaths occur before delivery, so we have to offer early detection and treatment. Each time we see the pregnant women we do a finger prick blood smear, we check for malaria and we treat very early. There is a 50% chance that if she had malaria, the parasites will come back, so we need to follow up right up to delivery. For delivery, we really encourage all women to birth with trained and skilled birth attendants, because they have the skills and the resources to prevent the unexpected events during childbirth.

Q: What are the most important lines of research that have emerged in the last 5-10 years?

RMG: I think artemisinins, that we now know can be used safely in pregnancies, is number one and have saved many lives. In 2001 we introduced ultrasounds in our setting and that was a big challenge. The clinics are made of bamboo, we get surges in the electric supply, certain insects favour the warm and dry insides of the machine. Once we got over that, we could document what happens in early pregnancy. Malaria is associated with miscarriage. More of a problem, when we talk about those babies who are born too small - that is actually that's happening very early in pregnancy, which brings into question how we can control malaria.

We have also looked at antibody responses throughout the length of pregnancy. It is quite hard to follow a woman for nine months, so this work is very importantly for vaccine studies. We have continued to work on vivax malaria; in fact 90% of our vivax infection is emerging from the liver. Our main problem is that the only drug we have for the liver stage, we can't use it in pregnant women, which makes things difficult.

Q: Why does your line of research matter and why should we fund it?

RMG: I think if we can have a pregnancy free from malaria parasites - this is the most common parasitic infection of humans - then we will decrease infant and maternal mortality and morbidity significantly. If we can get that early in utero environment healthy, then this child has a chance at a productive life. That's just one individua,l but we are talking about malaria endemic countries and it can have a huge financial impact.

Q: How does your work fit into translational medicine within the department?

RMG: We documented artesunate use in pregnancies since 1992, slowly and carefully, every time we had to give that treatment. This has formed the backbone of evidence for the World Health Organisation to change their guidelines for pregnant women. The new findings on the early pregnancy effects that we have worked out with ultrasound, these are more challenging because our current policy is to treat pregnant women from the second trimester with antimalarials, but the early work says that is too late. So we need to rethink how we work. We could take a lesson from the West: then a woman has a disease we ask her to come early, to see her GP and we optimise her health before conception. If we could do that in resource-limited settings, we can take on a lot - we can look at anaemia, malaria, worms and sexually transmitted infections, and really optimise health before conception.

Rose McGready

Professor Rose McGready works on the treatment and epidemiology of uncomplicated malaria in pregnancy. Pregnant women are particularly vulnerable as pregnancy reduces the immunity to malaria, increasing the susceptibility to malaria infection and the risk of illness, severe anaemia and death. For the unborn child, maternal malaria increases the risk of spontaneous abortion, stillbirth, premature delivery and low birth weight - a leading cause of child mortality.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.